Skip to main content

Table 4 Univariable and multivariable Cox proportional hazard analysis of factors associated with overall survival

From: High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin

 

Univariable

Multivariable

HR

P

HR

P

Age

 

0.512

  

  ≤ 65

1

   

  > 65

1.127 (0.788–1.610)

   

Sex

 

0.452

  

 Male

0.872 (0.610–1.246)

   

 Female

1

   

ECOG PS

 

0.090

 

0.092

 0

1

 

1

 

  ≥ 1

1.355 (0.953–1.926)

 

1.372 (0.949–1.984)

 

Charlson Commorbidity index

 

0.730

  

 0

1

   

  ≥ 1

1.066 (0.742–1.530)

   

Chronic hepatitis B

 

0.246

  

 No

1

   

 Yes

1.328 (0.822–2.144)

   

Chronic hepatitis C

 

0.736

  

 No

1

   

 Yes

1.187 (0.437–3.230)

   

Liver cirrhosis

 

0.134

  

 No

1

   

 Yes

1.531 (0.877–2.673)

   

Biliary drainage

 

0.884

  

 No

1

   

 Yes

1.043 (0.597–1.821)

   

Tumor size

 

0.207

  

  ≤ 7 cm

1

   

  > 7 cm

0.799 (0.564, 1.132)

   

Vascular invasion

 

0.346

  

 No

1

   

 Yes

0.841 (0.587, 1.206)

   

Hilar invasion

 

0.752

  

 No

1

   

 Yes

0.914 (0.524, 1.596)

   

Liver metastasis

 

0.686

  

 No

1

   

 Yes

0.930 (0.654–1.322)

   

Extrahepatic organ metastasis

 

0.108

  

 No

1

   

 Yes

1.332 (0.939–1.889)

   

Distant lymph node metastasis

 

< 0.001

 

< 0.001

 No

1

 

1

 

 Yes

1.906 (1.309–2.775)

 

1.929 (1.305–2.851)

 

Number of metastatic sites

    

 0

1

   

 1

2.753 (1.292–5.864)

0.009

  

  ≥ 2

2.987 (1.434–6.221)

0.003

  

Total bilirubin

 

0.604

  

  ≤ 1.5 x ULN

1

   

  > 1.5 x ULN

1.209 (0.590–2.480)

   

Alkaline phosphatase

 

0.008

 

0.125

  ≤ 1.5 x ULN

1

 

1

 

  > 1.5 x ULN

1.632 (1.138–2.340)

 

1.337 (0.923–1.939)

 

Albumin

 

0.001

 

0.043

  < 3.5 g/dL

2.268 (1.424–3.610)

 

1.632 (1.017–2.618)

 

  ≥ 3.5 g/dL

1

 

1

 

CA 19–9

 

0.530

  

  ≤ 37 U/mL

1

   

  > 37 U/mL

1.118 (0.790–1.583)

   

PLR

 

< 0.001

 

0.002

  ≤ 148

1

 

1

 

  > 148

2.332 (1.610–3.378)

 

1.856 (1.266–2.723)

 

NLR

 

< 0.001

  

  ≤ 5

1

   

  > 5

2.273 (1.471–3.512)

   

LMR

 

< 0.001

 

0.041

  < 3.5

2.423 (1.516–3.875)

 

1.691 (1.023–2.797)

 

  ≥ 3.5

1

 

1

 

AGR

 

0.002

  

  < 1.2

1.768 (1.236–2.528)

   

  ≥ 1.2

1

   
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; CA 19–9 Carbohydrate antigen 19–9; PLR Platelet-to-lymphocyte ratio; NLR Neutrophil-to-lymphocyte ratio; LMR Lymphocyte-to-monocyte ratio; AGR Albumin-to-globulin ratio